Rethinking The Clinical Trial (Video)

Highlights from the 2014 Medical Innovation Summit

By their nature, genomically targeted cancer therapies work well in the subset of patients they were designed for, but less well or not at all in other patients with the same cancer type. What will that mean for the design of clinical trials? Cleveland Clinic Taussig Cancer Institute Chairman Brian Bolwell, MD, explores the question.